| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.10(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,459 |
| 52
Week Range: |
$2.7 - $7.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Terreri Peter R |
Director |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
42,017 |
|
- |
|
| Chao Allen |
Director |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
52,795 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
55,825 |
|
- |
|
| Ben-Maimon Carole |
President, Global Pharm. |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,800 |
51,297 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,800 |
89,730 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,800 |
61,716 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
14,800 |
36,241 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2013-05-13 |
4 |
AS |
$17.44 |
$11,615 |
D/D |
(666) |
36,317 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2013-05-11 |
4 |
D |
$17.00 |
$20,281 |
D/D |
(1,193) |
64,930 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-05-11 |
4 |
D |
$17.00 |
$102,017 |
D/D |
(6,001) |
615,059 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-05-08 |
4 |
AS |
$16.35 |
$24,525 |
D/D |
(1,500) |
50,125 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2013-05-06 |
4 |
OE |
$8.00 |
$60,000 |
D/D |
7,500 |
36,983 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2013-05-01 |
4 |
AS |
$17.39 |
$59,996 |
D/D |
(3,450) |
29,483 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-04-13 |
4 |
D |
$16.46 |
$3,177 |
I/I |
(193) |
161,639 |
|
- |
|
| Reasons Bryan M. |
Chief Financial Officer |
• • – |
2013-04-13 |
4 |
D |
$16.46 |
$19,077 |
D/D |
(1,159) |
21,441 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-04-10 |
4 |
AS |
$15.97 |
$23,955 |
D/D |
(1,500) |
51,625 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-04-09 |
4 |
OE |
$8.00 |
$60,000 |
D/D |
7,500 |
53,125 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-04-08 |
4 |
AS |
$16.20 |
$97,200 |
D/D |
(6,000) |
7,999 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-04-08 |
4 |
OE |
$6.55 |
$39,300 |
D/D |
6,000 |
13,999 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-04-01 |
4 |
AS |
$15.31 |
$91,860 |
D/D |
(6,000) |
7,999 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-04-01 |
4 |
OE |
$6.55 |
$39,300 |
D/D |
6,000 |
13,999 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-03-25 |
4 |
AS |
$15.60 |
$93,600 |
D/D |
(6,000) |
7,999 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-03-25 |
4 |
OE |
$6.55 |
$39,300 |
D/D |
6,000 |
13,999 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-03-13 |
4 |
AS |
$16.69 |
$25,035 |
D/D |
(1,500) |
45,625 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2013-03-12 |
4 |
B |
$16.73 |
$16,728 |
D/D |
1,000 |
36,916 |
2.74 |
- |
|
531 Records found
|
|
Page 11 of 22 |
|
|
0.11 (1.57%) 
